Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Hanmi-Pharmaceutical

More Like This

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

PR Newswire associated0

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

PR Newswire associated0

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

ACCESSWIRE logo

HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

PR Newswire associated0

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published